Esperoct Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high bleeding risk in hemophilia a patients, dependence on frequent factor viii infusions, clinical advances in recombinant clotting factors, hospital-based hemophilia management, growing awareness of prophylaxis.

The growth in the forecast period can be attributed to increasing adoption of extended half-life therapies, expansion of homecare treatment models, rising hemophilia diagnosis rates, improved patient adherence, supportive reimbursement for rare diseases. Major trends in the forecast period include long-acting clotting factor therapies, shift toward prophylactic hemophilia care, reduced infusion frequency treatments, improved quality of life in hemophilia, expansion of home infusion programs.

The increasing incidence of bleeding disorders is expected to drive the growth of the esperoct market in the coming years. Bleeding disorders are medical conditions that impair the blood’s ability to clot properly, resulting in excessive or prolonged bleeding. The rising incidence of these disorders can be attributed to improved diagnosis, greater awareness, genetic factors, and an aging population, which together lead to higher detection rates. Esperoct is used to treat bleeding disorders, particularly hemophilia A, by replacing the missing clotting factor VIII, helping prevent or manage bleeding episodes in affected patients. For example, in May 2025, Pfizer, a US-based biopharmaceutical company, reported that the hemophilia A and B patient population in the UK exceeded 11,800 individuals during the 2023/2024 period. Therefore, the growing incidence of bleeding disorders is fueling the expansion of the esperoct market.

Rising healthcare investments are also expected to support the growth of the esperoct market. Healthcare investments involve allocating financial resources to the healthcare sector, including funding for facilities, technologies, pharmaceutical companies, medical research, and related services. These investments are increasing due to rising demand for advanced medical technologies, the needs of aging populations, expanding healthcare requirements, and efforts to drive innovations in treatments, pharmaceuticals, and disease prevention. Esperoct contributes to these investments by offering a therapeutic solution for hemophilia A, fostering development of innovative treatments, expanding access to specialized care, and improving patient outcomes through advanced biotechnology. For example, in November 2024, the Health Foundation, a UK-based independent charity, reported that planned healthcare spending is projected to rise from approximately $221.1 billion (£177.9 billion) to $237.4 billion (£190.1 billion) in 2024/25, and further increase to $250.1 billion (£200.5 billion) in 2025/26. Therefore, growing healthcare investments are driving the expansion of the esperoct market.

A significant trend in the esperoct market is obtaining regulatory approvals to broaden accessibility across global markets. Regulatory approvals involve official authorization by government agencies, such as the FDA or EMA, allowing a drug or medical product to be legally marketed after confirming its safety, efficacy, and quality. For instance, in October 2023, the Therapeutic Goods Administration (TGA), an Australian government agency, approved Esperoct (turoctocog alfa pegol) as a new biological entity for the treatment of hemophilia A. This medication is indicated for routine prophylaxis to prevent bleeding episodes, on-demand treatment of bleeding, and perioperative management. Esperoct works by temporarily correcting factor VIII deficiency, a critical component in managing this serious bleeding disorder. The approval followed a comprehensive evaluation of its quality, safety, and efficacy, and it is also monitored under Australia’s Black Triangle Scheme to strengthen pharmacovigilance for newly authorized medicines.

Major companies operating in the esperoct market are Novo Nordisk A/S.

North America was the largest region in the esperoct market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esperoct market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the esperoct market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the esperoct market by raising costs for recombinant protein production inputs, cold-chain logistics, and specialized biomanufacturing equipment. These increases affect hospitals and specialty clinics that rely on imported clotting factor therapies, particularly in Europe and North America. Pricing pressures have influenced long-term treatment affordability. At the same time, tariffs are accelerating domestic production investments and strengthening regional biologics supply chains for rare disease therapies.

The esperoct market research report is one of a series of new reports that provides esperoct market statistics, including esperoct industry global market size, regional shares, competitors with a esperoct market share, detailed esperoct market segments, market trends and opportunities, and any further data you may need to thrive in the esperoct industry. This esperoct market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Esperoct (efanesoctocog alfa) is a long-acting recombinant factor VIII therapy developed to treat hemophilia A by replacing the missing clotting factor and preventing bleeding episodes. Its extended formulation reduces the frequency of infusions, improving patient convenience and quality of life.

The primary treatment approaches with esperoct are prophylaxis and on-demand therapy. Prophylaxis involves actions or measures taken to prevent the occurrence of disease or health complications. It covers various clinical applications, including routine prophylaxis, perioperative management, and use across different age groups, and serves end users such as hospitals, specialty clinics, and homecare settings.

The esperoct market consists of sales of products including octocog alfa, kovaltry, recombinant factor VIII. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.